<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431342</article-id><article-id pub-id-type="pmcid-ver">PMC12431342.1</article-id><article-id pub-id-type="pmcaid">12431342</article-id><article-id pub-id-type="pmcaiid">12431342</article-id><article-id pub-id-type="pmid">40938886</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0332471</article-id><article-id pub-id-type="publisher-id">PONE-D-25-34080</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Bacterial Toxins</subject><subj-group><subject>Botulinum Toxin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Bacterial Toxins</subject><subj-group><subject>Botulinum Toxin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Head</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Head</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Eyes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Equipment</subject><subj-group><subject>Optical Equipment</subject><subj-group><subject>Prisms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anesthesiology</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>General Anesthesia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>General Anesthesia</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Ocular Anatomy</subject><subj-group><subject>Eye Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Ocular System</subject><subj-group><subject>Ocular Anatomy</subject><subj-group><subject>Eye Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Predictive Toxicology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Predictive Toxicology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pediatrics</subject></subj-group></subj-group></article-categories><title-group><article-title>Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia</article-title><alt-title alt-title-type="running-head">BTXA in childhood-acquired comitant esotropia</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-9851-6883</contrib-id><name name-style="western"><surname>Rattanalert</surname><given-names initials="N">Narisa</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nonboonyawat</surname><given-names initials="T">Teechaya</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1409-512X</contrib-id><name name-style="western"><surname>Tengtrisorn</surname><given-names initials="S">Supaporn</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singha</surname><given-names initials="P">Penny</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1697-1798</contrib-id><name name-style="western"><surname>Aryasit</surname><given-names initials="O">Orapan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4153-6384</contrib-id><name name-style="western"><surname>Witthayaweerasak</surname><given-names initials="J">Juthamat</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tangthongkum</surname><given-names initials="M">Manupol</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Pawar</surname><given-names initials="N">Neelam</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Aravind Eye Hospital, INDIA</addr-line>
</aff><author-notes><corresp id="cor001">* E-mail: <email>narisa.r@psu.ac.th</email></corresp><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496058</issue-id><elocation-id>e0332471</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 12:25:22.357"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Rattanalert et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Rattanalert et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0332471.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0332471.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938886"><article-title>Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia.</article-title><volume>20</volume><issue>9</issue><date><day>12</day><month>9</month><year>2025</year></date><fpage>e0332471</fpage><lpage>e0332471</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0332471</pub-id><pub-id pub-id-type="pmid">40938886</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938886"><article-title>Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia.</article-title><volume>20</volume><issue>9</issue><date><day>12</day><month>9</month><year>2025</year></date><fpage>e0332471</fpage><lpage>e0332471</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0332471</pub-id><pub-id pub-id-type="pmid">40938886</pub-id></related-article><abstract><sec id="sec001"><title>Purpose</title><p>This study aimed to assess the efficacy of botulinum toxin type A in treating childhood-acquired comitant esotropia and identify predictive factors of treatment success.</p></sec><sec id="sec002"><title>Methods</title><p>This retrospective, consecutive, non-comparative cohort study included children under 18 years treated with botulinum toxin type A for acquired comitant esotropia between 2013 and 2019, with a minimum 6-month follow-up. The primary outcome was the success rate of achieving horizontal deviation within 10 prism dioptres at 6 months post-botulinum toxin type A treatment.</p></sec><sec id="sec003"><title>Results</title><p>In total, 49 children with a mean treatment age 8.10&#8201;&#177;&#8201;4.02 years were assessed. The three most common types of esotropia were acute acquired comitant, intermittent, and cyclic esotropia (57.2%, 20.4%, and 12.2%, respectively). The mean esodeviation at near and distance was 42.55&#8201;&#177;&#8201;13.39 and 42.65&#8201;&#177;&#8201;13.35 prism dioptres, respectively. The botulinum toxin type A treatment success rate was 51% (25/49), with survival analysis indicating a declining cumulative probability of treatment success over time (48%, 28%, and 21% at 12, 18, and 24 months, respectively). Significant predictive factors for successful outcomes were pre-botulinum toxin type A esodeviation &gt;30&#8211;50 prism dioptres (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.008) and time from diagnosis to treatment &lt;2 months (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.001).</p></sec><sec id="sec004"><title>Conclusion</title><p>Botulinum toxin type A demonstrated a success rate of 51% at 6 months with pre-botulinum toxin type A esodeviation and early treatment identified as predictive factors for treatment success suggesting its clinical application.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100010804</institution-id><institution>Faculty of Medicine, Prince of Songkla University</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-9851-6883</contrib-id><name name-style="western"><surname>Rattanalert</surname><given-names>Narisa</given-names></name></principal-award-recipient></award-group><funding-statement>Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. Funder has no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The data contain potentially identifying patient information and are subject to restrictions imposed by the Ethics Committee of the Faculty of Medicine, Prince of Songkla University, to protect participant privacy. Qualified researchers who meet the criteria for access to confidential data may request access by contacting the Research Ethics Committee, Faculty of Medicine, Prince of Songkla University (email: <email>medpsu.ec@gmail.com</email>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The data contain potentially identifying patient information and are subject to restrictions imposed by the Ethics Committee of the Faculty of Medicine, Prince of Songkla University, to protect participant privacy. Qualified researchers who meet the criteria for access to confidential data may request access by contacting the Research Ethics Committee, Faculty of Medicine, Prince of Songkla University (email: <email>medpsu.ec@gmail.com</email>).</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Esotropia, a form of strabismus, involves an inward deviation of ocular alignment, where one eye turns inward. Childhood-acquired comitant esotropia is commonly seen in paediatric ophthalmology clinics with patients typically seeking medical attention within the first decade of life. Esotropia manifests in accommodative or non-accommodative forms [<xref rid="pone.0332471.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0332471.ref002" ref-type="bibr">2</xref>] and often leads to diplopia, diminished stereopsis and binocularity, or blurred vision in the affected eye, negatively impacting the patient&#8217;s vision and potentially causing amblyopia. Psychosocially, this condition can affect the patient&#8217;s self-esteem, interpersonal relationships, and access to vocational opportunities [<xref rid="pone.0332471.ref003" ref-type="bibr">3</xref>]. Treatment options for esotropia include glasses, prisms, occlusion, botulinum toxin, and extraocular muscle surgery, aiming to correct the deviation of the eyes [<xref rid="pone.0332471.ref004" ref-type="bibr">4</xref>].</p><p>Surgery has long been the established standard treatment for acquired comitant esotropia, with extraocular muscle surgery widely recognised as the primary approach. Several studies have reported satisfactory outcomes and a success rate of 50&#8211;84% with surgery [<xref rid="pone.0332471.ref005" ref-type="bibr">5</xref>&#8211;<xref rid="pone.0332471.ref009" ref-type="bibr">9</xref>]. However, an alternative treatment trend has emerged, focusing on the use of botulinum toxin type A (BTXA) for comitant esotropia. Scott AB [<xref rid="pone.0332471.ref010" ref-type="bibr">10</xref>] was the pioneer who introduced the use of BTXA for adult strabismus, paving the way for non-surgical methods in strabismus treatment. Subsequently, the application of BTXA in strabismus, particularly in treating esotropia, has gained wide acceptance with studies confirming its safety and effectiveness [<xref rid="pone.0332471.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0332471.ref011" ref-type="bibr">11</xref>&#8211;<xref rid="pone.0332471.ref015" ref-type="bibr">15</xref>]. Additionally, systematic reviews in 2017 showed no significant difference in the effectiveness of botulinum toxin therapy compared with conservative or surgical treatments. They indicated only a slight reduction in the likelihood of achieving correct alignment of the eyes in the botulinum toxin group. However, these trials were noted to have low-certainty evidence due to potential selection bias and methodological limitations [<xref rid="pone.0332471.ref004" ref-type="bibr">4</xref>].</p><p>These varied outcomes have raised concerns regarding the effectiveness of BTXA as a treatment for children with acquired comitant esotropia. Therefore, this study ascertained the success rate of BTXA and identify predictive factors associated with successful outcomes using a single BTXA injection in childhood-acquired comitant esotropia.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Patient selection</title><p>This retrospective, consecutive, non-comparative cohort study was conducted at Songklanagarind Hospital, Thailand. This study was approved by the Human Research Ethics Committee (HREC), Faculty of Medicine, Prince of Songkla University (REC.63-008-2-4, Date 2020-03-18), and adhered to the principles of the Declaration of Helsinki. The need for informed consent was waived due to the retrospective and de-identified nature of the data analysed as per the HREC guidelines.</p><p>Electronic medical records of children under 18 years of age, diagnosed with acquired comitant esotropia (with an angle of esodeviation not varying by &gt;5 prism dioptres [PD] in all gaze positions or with either eye fix) who underwent BTXA treatment between January 2013 and December 2019, with a follow-up duration of at least 6 months, were reviewed. Acute acquired comitant esotropia was defined as the acute onset of esotropia or diplopia within six months of presentation. Partial accommodative esotropia was diagnosed in patients with hyperopia of +3.00 dioptres (D) or more and a reduction of esotropia by at least 10 PD following hyperopic correction. Intermittent esotropia was defined as esotropia that presented intermittently in patients with hyperopia of less than +3.00 D. Non-refractive accommodative esotropia was characterized by a near deviation exceeding the distance deviation by more than 10 PD. Cyclic esotropia was defined as esotropia occurring in a regular cycle, typically every 24 or 48 hours. Patients with esotropia associated with neurological disorders, developmental abnormalities, prior ocular surgery, or previous strabismus surgery were excluded from study. Electronic medical records were accessed for research purposes between March 20, 2020, and December 30, 2023. All data were de-identified in the recorded form. The authors had access to identifiable information during the data collection phase, but not after data collection was completed.</p></sec><sec id="sec008"><title>Data collection</title><p>Baseline characteristics, including sex, age at treatment, symptom duration, types of acquired esotropia, visual acuity, refraction (expressed as spherical equivalent [sphere power&#8201;+&#8201;half of cylinder power, dioptres]), presence of diplopia, amblyopia status, time from diagnosis to treatment, and follow-up duration, were recorded. All patients were administered an intramuscular injection of 7.5 units of BTXA (Dysport&#174;) into the medial rectus muscle in both eyes using forceps, without conjunctival incision or electromyographic guidance, by paediatric ophthalmologists in either the operative room under general anaesthesia or outpatient department under topical anaesthesia. Two patients with esotropia of 30 and 35 PD, who received a unilateral injection of 7.5 units of BTXA into the medial rectus muscle, were excluded to ensure more reliable data and to better assess the effectiveness of BTXA treatment. The angle of deviation, stereoacuity, complications, and any additional treatments were recorded during each visit. The primary outcome was the success rate of achieving horizontal deviation within 10 PD at 6 months post-BTXA treatment. Secondary outcomes included binocularity status and identification of predictive factors for successful treatment. Recurrent esotropia was defined as the reappearance of esotropia after an initially successful alignment outcome at 6 months following BTXA treatment.</p></sec><sec id="sec009"><title>Statistical analysis</title><p>Data were analysed using the R program version 4.1.0 (The R Group, Vienna, Austria) with the Epicalc software [<xref rid="pone.0332471.ref016" ref-type="bibr">16</xref>]. Descriptive statistics, including frequency, mean&#8201;&#177;&#8201;standard deviation, and median and interquartile range (IQR), were calculated. The Wilcoxon signed-rank test was used to compare pre-BTXA and post-BTXA angles of deviation. The chi-squared test or Fisher&#8217;s exact test was used to assess categorical variables. Continuous variables were analysed using the Mann&#8211;Whitney U test or independent t-test. <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was considered statistically significant. Univariate and multivariate logistic regression analyses were performed to predict factors associated with successful outcomes. Primary outcome analysis was restricted to the results following the initial BTXA injection. Data from subsequent interventions were presented separately for descriptive purposes and were not included in the primary success rate calculation. The Kaplan&#8211;Meier method (Lawless, 1982<sup>&#8204;&#8204;</sup>) was used to calculate the probability of treatment success over time, considering treatment failure or esotropia recurrence as events, and successful follow-up as censoring events.</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><sec id="sec011"><title>Patients and disease characteristics</title><p>Forty-nine patients were included in the study. Baseline characteristics (<xref rid="pone.0332471.t001" ref-type="table">Table 1</xref>) revealed a male-to-female ratio of 2:1. The mean age at treatment initiation was 8.10&#8201;&#177;&#8201;4.02 years. The three most prevalent types of esotropia were acute acquired comitant, intermittent, and cyclic esotropia. The mean time from diagnosis to treatment was 4.67 months, with a mean follow-up duration of 23 months. Among the patients, 16.3% presented with pre-treatment amblyopia.</p><table-wrap position="float" id="pone.0332471.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332471.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332471.t001g" position="float" orientation="portrait" xlink:href="pone.0332471.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Baseline characteristics</th><th align="left" rowspan="1" colspan="1">N&#8201;=&#8201;49 (%) or mean&#8201;&#177;&#8201;SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male sex</td><td align="left" rowspan="1" colspan="1">32 (65.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at treatment (years)</td><td align="left" rowspan="1" colspan="1">8.10&#8201;&#177;&#8201;4.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptoms duration before diagnosis (months)</td><td align="left" rowspan="1" colspan="1">3.99&#8201;&#177;&#8201;5.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Time of diagnosis to treatment (months)</td><td align="left" rowspan="1" colspan="1">4.67&#8201;&#177;&#8201;7.27</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Types of acquired esotropia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Acute acquired comitant esotropia</td><td align="left" rowspan="1" colspan="1">28 (57.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Intermittent esotropia</td><td align="left" rowspan="1" colspan="1">10 (20.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cyclic esotropia</td><td align="left" rowspan="1" colspan="1">6 (12.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Partially accommodative esotropia</td><td align="left" rowspan="1" colspan="1">3 (6.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-refractive accommodative esotropia</td><td align="left" rowspan="1" colspan="1">2 (4.1)</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Visual acuity (LogMAR)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Right eye</td><td align="left" rowspan="1" colspan="1">0.18&#8201;&#177;&#8201;0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Left eye</td><td align="left" rowspan="1" colspan="1">0.15&#8201;&#177;&#8201;0.14</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Refraction (dioptres)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Right eye</td><td align="left" rowspan="1" colspan="1">0.20&#8201;&#177;&#8201;1.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Left eye</td><td align="left" rowspan="1" colspan="1">0.41&#8201;&#177;&#8201;1.89</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Amblyopia</bold>
</td><td align="left" rowspan="1" colspan="1">8 (16.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Strabismic amblyopia</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Combined strabismic and refractive amblyopia</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Diplopia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">15 (30.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">20 (40.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No available data</td><td align="left" rowspan="1" colspan="1">14 (28.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-BTXA esotropia at near (PD)</td><td align="left" rowspan="1" colspan="1">42.55&#8201;&#177;&#8201;13.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-BTXA esotropia at distance (PD)</td><td align="left" rowspan="1" colspan="1">42.65&#8201;&#177;&#8201;13.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up duration (months)</td><td align="left" rowspan="1" colspan="1">23.02&#8201;&#177;&#8201;16.32</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><italic toggle="yes">BTXA</italic> botulinum toxin type A, <italic toggle="yes">LogMAR</italic> logarithm of the minimum angle of resolution, <italic toggle="yes">PD</italic> prism dioptres, <italic toggle="yes">SD</italic> standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec012"><title>Success rate of BTXA</title><p>The success rate of initial BTXA treatment at 6 months was 51% (25/49) in the overall cohort and 60.7% (17/28) among patients with acute acquired comitant esotropia. Among the 25 patients who achieved successful motor outcomes at 6 months, binocularity data were available for 23. Of these, 22 demonstrated functional binocular vision; all achieved fusion, and 19 achieved stereopsis. The median stereopsis was 40 seconds of arc (IQR: 25&#8211;80).</p><p>In the subgroup with acute acquired comitant esotropia, binocularity data were available for 16 of 17 patients. All 16 achieved binocular function, with a median stereopsis of 40 seconds of arc (IQR: 25&#8211;80).</p><p>Seven patients in the success group (28%) experienced recurrent esotropia following the initial BTXA injection, with a mean time to recurrence of 14.84&#8201;&#177;&#8201;3.55 months. Among them, four patients underwent secondary interventions (one muscle surgery and three additional BTXA treatments), achieving a success rate of 75% for the second intervention.</p><p>The mean time to failed treatment was 2.59&#8201;&#177;&#8201;1.91 months in the treatment failure group. In this group, 84% (21/25) patients underwent a secondary intervention, specifically, 18 patients underwent muscle surgery and 3 underwent repeat BTXA treatments. The success rates for the secondary interventions were 55.5% (10/18) for muscle surgery and 33.3% (1/3) for BTXA.</p><p>Post-BTXA complications occurred in 49% (24/49) patients, including ptosis (n&#8201;=&#8201;10), overcorrection (n&#8201;=&#8201;6), combined ptosis and overcorrection (n&#8201;=&#8201;6), and subconjunctival haemorrhage (n&#8201;=&#8201;2). No further medical or surgical intervention was performed for these complications. Overcorrections resolved over time, within 5&#8211;20 weeks.</p><p>Comparison of characteristics between the success and failure groups revealed statistically significant differences in pre-BTXA esotropia (&gt;30&#8211;50 PD) at near (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.002) and distance (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.016), time from diagnosis to treatment (&lt;2 months; <italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.001), and follow-up duration (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.001; <xref rid="pone.0332471.t002" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="pone.0332471.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332471.t002</object-id><label>Table 2</label><caption><title>Comparison characteristics between the success and failure groups.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332471.t002g" position="float" orientation="portrait" xlink:href="pone.0332471.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Success group<break/>N&#8201;=&#8201;25 (%) or mean&#8201;&#177;&#8201;SD</th><th align="left" rowspan="1" colspan="1">Failure group<break/>N&#8201;=&#8201;24 (%) or mean&#8201;&#177;&#8201;SD</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value*</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">18 (72.0)</td><td align="left" rowspan="1" colspan="1">14 (58.3)</td><td align="left" rowspan="1" colspan="1">0.315</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="left" rowspan="1" colspan="1">7 (28.0)</td><td align="left" rowspan="1" colspan="1">10 (41.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at treatment (years)</bold>
</td><td align="left" rowspan="1" colspan="1">8.42&#8201;&#177;&#8201;4.53</td><td align="left" rowspan="1" colspan="1">7.77&#8201;&#177;&#8201;3.48</td><td align="left" rowspan="1" colspan="1">0.578</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Symptom duration (months)</bold>
</td><td align="left" rowspan="1" colspan="1">4.07&#8201;&#177;&#8201;5.47</td><td align="left" rowspan="1" colspan="1">3.92&#8201;&#177;&#8201;5.50</td><td align="left" rowspan="1" colspan="1">0.920</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Types of acquired esotropia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Acute acquired comitant esotropia</td><td align="left" rowspan="1" colspan="1">17 (70.8)</td><td align="left" rowspan="1" colspan="1">11 (45.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Intermittent esotropia</td><td align="left" rowspan="1" colspan="1">3 (12.5)</td><td align="left" rowspan="1" colspan="1">6 (25.0)</td><td align="left" rowspan="1" colspan="1">0.259</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cyclic esotropia</td><td align="left" rowspan="1" colspan="1">1 (4.2)</td><td align="left" rowspan="1" colspan="1">5 (20.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Partially accommodative esotropia</td><td align="left" rowspan="1" colspan="1">2 (8.3)</td><td align="left" rowspan="1" colspan="1">1 (4.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-refractive accommodative esotropia</td><td align="left" rowspan="1" colspan="1">1 (4.2)</td><td align="left" rowspan="1" colspan="1">1 (4.2))</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Amblyopia status</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">4 (16.0)</td><td align="left" rowspan="1" colspan="1">4 (16.7)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">21 (84.0)</td><td align="left" rowspan="1" colspan="1">20 (83.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pre&#8211;BTXA esotropia at near</bold>
</td><td align="left" rowspan="1" colspan="1">40.60&#8201;&#177;&#8201;7.12</td><td align="left" rowspan="1" colspan="1">44.58&#8201;&#177;&#8201;17.69</td><td align="left" rowspan="1" colspan="1">0.303</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8804; 30 PD</td><td align="left" rowspan="1" colspan="1">2 (8.0)</td><td align="left" rowspan="1" colspan="1">8 (33.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 30&#8211;50 PD</td><td align="left" rowspan="1" colspan="1">23 (92.0)</td><td align="left" rowspan="1" colspan="1">11 (45.8)</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 50 PD</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">5 (20.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pre&#8211;BTXA esotropia at distance</bold>
</td><td align="left" rowspan="1" colspan="1">40.4&#8201;&#177;&#8201;6.75</td><td align="left" rowspan="1" colspan="1">45.0&#8201;&#177;&#8201;17.69</td><td align="left" rowspan="1" colspan="1">0.232</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8804; 30 PD</td><td align="left" rowspan="1" colspan="1">3 (12.0)</td><td align="left" rowspan="1" colspan="1">6 (25.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 30&#8211;50 PD</td><td align="left" rowspan="1" colspan="1">22 (88.0)</td><td align="left" rowspan="1" colspan="1">13 (54.2)</td><td align="left" rowspan="1" colspan="1">
<bold>0.016</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 50 PD</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">5 (20.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Diplopia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">5 (33.3)</td><td align="left" rowspan="1" colspan="1">0.492</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">10 (66.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Time from diagnosis to treatment (months)</bold>
</td><td align="left" rowspan="1" colspan="1">2.58&#8201;&#177;&#8201;3.33</td><td align="left" rowspan="1" colspan="1">6.86&#8201;&#177;&#8201;9.45</td><td align="left" rowspan="1" colspan="1">
<bold>0.038</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805; 2 months</td><td align="left" rowspan="1" colspan="1">7 (28.0)</td><td align="left" rowspan="1" colspan="1">18 (75.0)</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt; 2 months</td><td align="left" rowspan="1" colspan="1">18 (72.0)</td><td align="left" rowspan="1" colspan="1">6 (25.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mean follow-up duration (months)</bold>
</td><td align="left" rowspan="1" colspan="1">15.49&#8201;&#177;&#8201;7.86</td><td align="left" rowspan="1" colspan="1">30.86&#8201;&#177;&#8201;19.12</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Anaesthesia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;General anaesthesia</td><td align="left" rowspan="1" colspan="1">18 (72.0)</td><td align="left" rowspan="1" colspan="1">20 (83.3)</td><td align="left" rowspan="1" colspan="1">0.496</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Topical anaesthesia</td><td align="left" rowspan="1" colspan="1">7 (28.0)</td><td align="left" rowspan="1" colspan="1">4 (16.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>1-month-post-BTXA alignment</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Within 10 PD</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">3 (60)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Overcorrection</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">2 (40)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>*Significant&#8201;&lt;&#8201;0.05.</p></fn><fn id="t002fn002"><p><italic toggle="yes">BTXA</italic> botulinum toxin type A, <italic toggle="yes">PD</italic> prism dioptres, <italic toggle="yes">SD</italic> standard deviation.</p></fn></table-wrap-foot></table-wrap><p>Additionally, the Kaplan&#8211;Meier curve depicting disease-free survival illustrated a 51% probability of treatment success at 6 months (95% confidence interval [CI] = 36.4&#8211;63.9). However, this probability of success declined to 48% at 12 months (95% CI&#8201;=&#8201;32.9&#8211;61.3), 28% at 18 months (95% CI&#8201;=&#8201;14&#8211;44.7) and 21% at 24 months (95% CI&#8201;=&#8201;7.5&#8211;39.7; <xref rid="pone.0332471.g001" ref-type="fig">Fig 1</xref>). The median disease-free survival time was 6 months (2.73&#8211;13.23).</p><fig position="float" id="pone.0332471.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332471.g001</object-id><label>Fig 1</label><caption><title>Kaplan&#8211;Meier analysis estimated the probability of treatment success for 49 patients as 51%, 48%, 28%, and 21% at 6-, 12-, 18-, and 24-months intervals, respectively.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332471.g001.jpg"/></fig></sec><sec id="sec013"><title>Predictive factors for successful outcome</title><p>Predictive factors associated with successful outcomes were analysed in the successful outcomes group at 6 months using univariate and multivariate logistic regression analyses (<xref rid="pone.0332471.t003" ref-type="table">Table 3</xref>). Pre-BTXA near esodeviation (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.008) and time from diagnosis to treatment (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.001) emerged as significant predictive factors for a successful outcome.</p><table-wrap position="float" id="pone.0332471.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332471.t003</object-id><label>Table 3</label><caption><title> Logistic regression analysis predicting factors of successful outcomes.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332471.t003g" position="float" orientation="portrait" xlink:href="pone.0332471.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="left" colspan="3" rowspan="1">Univariate</th><th align="left" colspan="3" rowspan="1">Multivariate</th></tr><tr><th align="left" rowspan="1" colspan="1">OR <break/>(95% CI)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value<break/>(wald-test)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value*<break/>(LR-test)</th><th align="left" rowspan="1" colspan="1">OR <break/>(95% CI)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value<break/>(wald-test)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value*<break/>(LR-test)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Types of acquired esotropia</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Acute acquired comitant esotropia</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.295</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Intermittent esotropia</td><td align="left" rowspan="1" colspan="1">0.43 (0.07, 1.89)</td><td align="left" rowspan="1" colspan="1">0.264</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cyclic esotropia</td><td align="left" rowspan="1" colspan="1">0.13 (0.01, 1.26)</td><td align="left" rowspan="1" colspan="1">0.078</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Partially accommodative esotropia</td><td align="left" rowspan="1" colspan="1">1.29 (0.10, 16.04)</td><td align="left" rowspan="1" colspan="1">0.841</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-refractive accommodative esotropia</td><td align="left" rowspan="1" colspan="1">0.65 (0.04, 11.45)</td><td align="left" rowspan="1" colspan="1">0.767</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Amblyopia status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.950</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1.05 (0.23, 4.78)</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pre&#8211;BTXA esotropia at near</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8804; 30 PD</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 30&#8211;50 PD</td><td align="left" rowspan="1" colspan="1">8.36 (1.52, 46.15)</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.97 (1.10, 44.13)</td><td align="left" rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pre&#8211;BTXA esotropia at distance</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8804; 30 PD</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt; 30&#8211;50 PD</td><td align="left" rowspan="1" colspan="1">3.38 (0.72, 15.89)</td><td align="left" rowspan="1" colspan="1">0.122</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Diplopia</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.322</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">0.50 (0.13, 1.99)</td><td align="left" rowspan="1" colspan="1">0.327</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Time from diagnosis to treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805; 2 months</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt; 2 months</td><td align="left" rowspan="1" colspan="1">7.71 (2.16, 27.50)</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.31 (1.51, 26.41)</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Time from symptom to treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805; 3 months</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.122</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt; 3 months</td><td align="left" rowspan="1" colspan="1">2.81 (0.73, 10.84)</td><td align="left" rowspan="1" colspan="1">0.133</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>1-month-post-BTXA alignment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Within 10 PD</td><td align="left" rowspan="1" colspan="1">1 (reference)</td><td align="left" rowspan="1" colspan="1">0.690</td><td align="left" rowspan="1" colspan="1">0.688</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Overcorrection</td><td align="left" rowspan="1" colspan="1">1.50 (0.20, 10.99)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>*Significant&#8201;&lt;&#8201;0.05.</p></fn><fn id="t003fn002"><p><italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">OR</italic> odd ratio, <italic toggle="yes">ND</italic> not done, <italic toggle="yes">NS</italic> not significant, <italic toggle="yes">BTXA</italic> botulinum toxin type A, <italic toggle="yes">PD</italic> prism dioptres.</p></fn></table-wrap-foot></table-wrap><p>The Kaplan&#8211;Meier curve for disease-free survival in patients with pre-BXTA esotropia indicated that &gt;30&#8211;50 PD at near and distance significantly influenced successful treatment. The probabilities of success were 67.7% (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>&lt;&#8201;0.001) and 62.9% (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>&lt;&#8201;0.001) at 6 months for near and distance, respectively (<xref rid="pone.0332471.g002" ref-type="fig">Fig 2</xref>). Additionally, time from diagnosis to treatment &lt;2 months was correlated with successful outcomes, with a 75% probability of success at 6 months (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>&lt;&#8201;0.001).</p><fig position="float" id="pone.0332471.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332471.g002</object-id><label>Fig 2</label><caption><title>Kaplan&#8211;Meier analysis estimated the probability of treatment success categorised by the range of pre-BTXA esodeviation at near (a) and distance (b), as well as time from diagnosis to treatment (c).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332471.g002.jpg"/></fig></sec></sec><sec sec-type="conclusions" id="sec014"><title>Discussion</title><p>Our study provides valuable insights into the success rate of BTXA treatment for acquired comitant esotropia in children and identifies predictive factors for successful outcomes. Overall, we observed a 51% success rate at 6 months post-BTXA. In cases of acute acquired comitant esotropia, the success rate was higher, at 60.7% (17 out of 28 patients). Additionally, pre-treatment esodeviation and time from diagnosis to treatment emerged as significant predictive factors for successful outcomes (<italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.008 and <italic toggle="yes"><italic toggle="yes">p</italic>&#8201;</italic>=&#8201;0.001, respectively). Acute acquired comitant, intermittent, and cyclic esotropia were the three most prevalent types of acquired esotropia observed in our study.</p><p>Although BTXA has been widely used in strabismic treatment, studies examining its long-term success rate and ideal candidates are limited [<xref rid="pone.0332471.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0332471.ref018" ref-type="bibr">18</xref>]. In this regard, our study revealed a 51% success rate with BTXA treatment, showing a decline in success over time. Nevertheless, approximately one-fifth of the patients sustained optimal outcomes beyond 2 years. Our Kaplan&#8211;Meier analysis confirmed a progressive decline in the probability of treatment success over time, with only 21% of patients maintaining optimal ocular alignment beyond two years. This trend underscores the importance of long-term follow-up to detect and manage recurrence in a timely manner. Overall, our findings align with previous studies [<xref rid="pone.0332471.ref018" ref-type="bibr">18</xref>], but show varying success rates compared with others. For instance, study by Wan et al. [<xref rid="pone.0332471.ref008" ref-type="bibr">8</xref>] reported higher success rates of BTXA at 81% and 67% at 6 and 18 months, respectively, for acute onset comitant esotropia, whereas our study revealed a 60.7% success rate in acute acquired comitant esotropia. However, they had a lower median esodeviation and a smaller study population (35 PD, n&#8201;=&#8201;16) compared to that of this study. Additionally, Yu et al. reported a success rate of 68.68% over a 2-year follow-up for acute acquired comitant esotropia and found that the number of hours spent on near work per day was a significant risk factor for esotropia recurrence (Hazard ratio: 1.29, 95% CI&#8201;=&#8201;1.00&#8211;1.67) [<xref rid="pone.0332471.ref019" ref-type="bibr">19</xref>]. Another study by Tejedor et al. reported a similar success rate of 52.9% with single BTXA, identifying higher hypermetropia, less severe amblyopia, and a smaller angle of esotropia, without specifying the exact angular deviations, as predictors of satisfactory outcomes [<xref rid="pone.0332471.ref015" ref-type="bibr">15</xref>]. In another study, Gama et al. [<xref rid="pone.0332471.ref020" ref-type="bibr">20</xref>] showed a 60% success rate with a single BTXA injection in nonaccommodative esotropia in children (n&#8201;=&#8201;25, mean esodeviation&#8201;=&#8201;27 PD) with long-lasting effects for up to 2 years. Study by Nguyen et al. reported 89% and 72% success rate at 6-month and 36-month follow-up in acute acquired comitant esotropia [<xref rid="pone.0332471.ref018" ref-type="bibr">18</xref>]. In contrast, our study showed a decline in success rate over time, likely due to the larger mean esodeviation in our patients and longer symptom duration before diagnosis. Nevertheless, our study highlighted that esodeviation &gt;30&#8211;50 PD was associated with a success rate similar to that reported by Hered et al. [<xref rid="pone.0332471.ref021" ref-type="bibr">21</xref>] suggesting that BTXA is most effective for small-to-moderate angle deviations (&lt;40 PD). This implies that BTXA is a reasonable treatment for moderate angle deviations. A meta-analysis by Song et al. found that BTXA treatment was as effective as muscle surgery for acute acquired comitant esotropia [<xref rid="pone.0332471.ref022" ref-type="bibr">22</xref>]. Therefore, BTXA is an alternative treatment in such cases. Additionally, our study showed a higher number of overcorrections in the success group, although no significant difference was observed between overcorrection at 1-month post-BTXA or alignment within 10 PD. This contrasts with the findings of Niyaz et al., who reported that early overcorrection is a better predictor of success [<xref rid="pone.0332471.ref023" ref-type="bibr">23</xref>].</p><p>Moreover, the incidence of BTXA complications in this study was higher than that in previous studies [<xref rid="pone.0332471.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0332471.ref024" ref-type="bibr">24</xref>]. Consistent with prior research, ptosis emerged as the most common complication, whereas subconjunctival haemorrhage was the least common complication. The increased complication rate might be attributed to the higher dosage of BTXA administered in our study. Furthermore, in our study, esotropia recurrence within 1&#8211;2 years of follow-up was observed in the successful group. Therefore, a minimum follow-up period of 2 years is mandatory. Consequently, we recommend a follow-up duration of at least 2 years for patients with successful BTXA treatment due to the risk of esotropia recurrence.</p><p>Overall, our study, with a substantial sample size, provides comprehensive insights into the success rate of BTXA as a treatment for childhood-acquired comitant esotropia. Additionally, the analysis of factors influencing successful outcome holds good validity, given the inclusion of predictive factors in multivariate analysis models. This underscores the potential benefits of BTXA as an alternative treatment for acquired esotropia. However, a notable limitation of this study was its retrospective, single-arm design, relatively small subgroup sizes for certain esotropia types, and variable follow-up durations. Our use of a horizontal deviation within 10 PD as the criterion for treatment success post-BTXA is consistent with previous studies and is generally associated with functional binocular vision. Nevertheless, we acknowledge that diplopia may still occur within this range, and our limited binocularity data at 6 months prevent definitive conclusions. This highlights the importance of incorporating both motor and sensory outcomes when defining treatment success. In addition to the identified predictive factors, lifestyle-related visual demands, such as prolonged near work and smartphone use, may influence both initial treatment outcomes and long-term stability. Previous reports have linked excessive screen use with acute acquired comitant esotropia and higher recurrence rates following BTXA or surgery. Although such data were not available in our cohort, these factors warrant further investigation. Therefore, future prospective, multicenter randomized controlled trials with standardized follow-up protocols are recommended to establish more robust evidence supporting the efficacy and safety of BTXA in childhood-acquired comitant esotropia. Nevertheless, the clinical implications of our study suggest that BTXA is an alternative treatment for childhood-acquired esotropia. While our observation that smaller-to-moderate angle deviations respond more favourably to BTXA is consistent with prior reports, our multivariate analysis further refined the predictive range to &gt;30&#8211;50 PD for optimal outcomes. Additionally, early intervention within 2 months of diagnosis emerged as an independent predictor of success, reinforcing the value of prompt referral and treatment. Particularly, BTXA application potentially reduces procedure time and allows for office-based administration, eliminating anaesthetic risks and the need for hospitalisation. Moreover, BTXA offers the potential to shorten general anaesthesia duration and reduce treatment and hospitalisation costs in younger children requiring general anaesthesia.</p></sec><sec sec-type="conclusions" id="sec015"><title>Conclusion</title><p>At 6 months, BTXA demonstrated a success rate of 51%. Pre-BTXA esodeviation and the time from diagnosis to treatment were identified as predictive factors for successful outcomes. Therefore, BTXA may be alternative treatment for childhood-acquired comitant esotropia for patients who present early and with an angle of deviation &gt;30&#8211;50 PD.</p></sec></body><back><ack><p>We are grateful to the research consultation department, Ms. Parichat Damthongsuk and Ms. Sujinda Damthong for their suggestions and assistance.</p></ack><ref-list><title>References</title><ref id="pone.0332471.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Greenberg</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Mohney</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Diehl</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>JP</given-names></name>. <article-title>Incidence and types of childhood esotropia: a population-based study</article-title>. <source>Ophthalmology</source>. <year>2007</year>;<volume>114</volume>(<issue>1</issue>):<fpage>170</fpage>&#8211;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2006.05.072</pub-id><pub-id pub-id-type="pmid">17070595</pub-id></mixed-citation></ref><ref id="pone.0332471.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mohney</surname><given-names>BG</given-names></name>. <article-title>Common forms of childhood strabismus in an incidence cohort</article-title>. <source>Am J Ophthalmol</source>. <year>2007</year>;<volume>144</volume>(<issue>3</issue>):<fpage>465</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2007.06.011</pub-id><pub-id pub-id-type="pmid">17765436</pub-id></mixed-citation></ref><ref id="pone.0332471.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dohlman</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Heidary</surname><given-names>G</given-names></name>. <article-title>The Impact of Strabismus on Psychosocial Equity</article-title>. <source>Semin Ophthalmol</source>. <year>2023</year>;<volume>38</volume>(<issue>1</issue>):<fpage>52</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/08820538.2022.2152701</pub-id><pub-id pub-id-type="pmid">36447371</pub-id></mixed-citation></ref><ref id="pone.0332471.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rowe</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Noonan</surname><given-names>CP</given-names></name>. <article-title>Botulinum toxin for the treatment of strabismus</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2017</year>;<volume>3</volume>(<issue>3</issue>):CD006499. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/14651858.CD006499.pub4</pub-id><pub-id pub-id-type="pmid">28253424</pub-id><pub-id pub-id-type="pmcid">PMC6464099</pub-id></mixed-citation></ref><ref id="pone.0332471.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scheiman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ciner</surname><given-names>E</given-names></name>. <article-title>Surgical success rates in acquired, comitant, partially accommodative and nonaccommodative esotropia</article-title>. <source>J Am Optom Assoc</source>. <year>1987</year>;<volume>58</volume>(<issue>7</issue>):<fpage>556</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="pmid">3312378</pub-id></mixed-citation></ref><ref id="pone.0332471.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Noh</surname><given-names>HJ</given-names></name>. <article-title>Surgical outcomes of acute acquired comitant esotropia of adulthood</article-title>. <source>BMC Ophthalmol</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>45</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12886-020-01793-3</pub-id><pub-id pub-id-type="pmid">33461540</pub-id><pub-id pub-id-type="pmcid">PMC7814435</pub-id></mixed-citation></ref><ref id="pone.0332471.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Merino</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Freire</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Y&#225;&#241;ez-Merino</surname><given-names>J</given-names></name>, <name name-style="western"><surname>G&#243;mez de Lia&#241;o</surname><given-names>P</given-names></name>. <article-title>Surgical outcomes of acquired acute comitant esotropia. Causes and classification</article-title>. <source>Arch Soc Esp Oftalmol (Engl Ed)</source>. <year>2022</year>;<volume>97</volume>(<issue>10</issue>):<fpage>558</fpage>&#8211;<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.oftale.2022.06.009</pub-id><pub-id pub-id-type="pmid">35871999</pub-id></mixed-citation></ref><ref id="pone.0332471.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Mantagos</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Kazlas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DG</given-names></name>. <article-title>Comparison of Botulinum Toxin With Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children</article-title>. <source>Am J Ophthalmol</source>. <year>2017</year>;<volume>176</volume>:<fpage>33</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2016.12.024</pub-id><pub-id pub-id-type="pmid">28057455</pub-id></mixed-citation></ref><ref id="pone.0332471.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ismail</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Abdelkader</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Mohamed</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Abdelaziz</surname><given-names>ST</given-names></name>. <article-title>Evaluation of Efficacy and Lateral Gaze Incomitance in Symmetrical and Asymmetrical Surgery for Concomitant Esotropia and Exotropia</article-title>. <source>Clin Ophthalmol</source>. <year>2021</year>;<volume>15</volume>:<fpage>3613</fpage>&#8211;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/OPTH.S326659</pub-id><pub-id pub-id-type="pmid">34471346</pub-id><pub-id pub-id-type="pmcid">PMC8405227</pub-id></mixed-citation></ref><ref id="pone.0332471.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scott</surname><given-names>AB</given-names></name>. <article-title>Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery</article-title>. <source>Ophthalmology</source>. <year>1980</year>;<volume>87</volume>(<issue>10</issue>):<fpage>1044</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0161-6420(80)35127-0</pub-id><pub-id pub-id-type="pmid">7243198</pub-id></mixed-citation></ref><ref id="pone.0332471.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dawson</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Marshman</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>GG</given-names></name>. <article-title>The role of botulinum toxin A in acute-onset esotropia</article-title>. <source>Ophthalmology</source>. <year>1999</year>;<volume>106</volume>(<issue>9</issue>):<fpage>1727</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0161-6420(99)90360-3</pub-id><pub-id pub-id-type="pmid">10485541</pub-id></mixed-citation></ref><ref id="pone.0332471.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lueder</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>Galli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tychsen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yildirim</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pegado</surname><given-names>V</given-names></name>. <article-title>Long-term results of botulinum toxin-augmented medial rectus recessions for large-angle infantile esotropia</article-title>. <source>Am J Ophthalmol</source>. <year>2012</year>;<volume>153</volume>(<issue>3</issue>):<fpage>560</fpage>&#8211;<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2011.08.019</pub-id><pub-id pub-id-type="pmid">21996305</pub-id></mixed-citation></ref><ref id="pone.0332471.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lang</surname><given-names>L-J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z-G</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>G-Y</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>H-Y</given-names></name>, <name name-style="western"><surname>Rong</surname><given-names>J-B</given-names></name>, <etal>et al</etal>. <article-title>Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>13869</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-019-50383-x</pub-id><pub-id pub-id-type="pmid">31554874</pub-id><pub-id pub-id-type="pmcid">PMC6761114</pub-id></mixed-citation></ref><ref id="pone.0332471.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tejedor</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guti&#233;rrez-Carmona</surname><given-names>FJ</given-names></name>. <article-title>Botulinum toxin in the treatment of partially accommodative esotropia with high AC/A ratio</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>2</issue>):e0229267. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0229267</pub-id><pub-id pub-id-type="pmid">32109950</pub-id><pub-id pub-id-type="pmcid">PMC7048305</pub-id></mixed-citation></ref><ref id="pone.0332471.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tejedor</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez</surname><given-names>JM</given-names></name>. <article-title>Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2001</year>;<volume>42</volume>(<issue>11</issue>):<fpage>2542</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="pmid">11581195</pub-id></mixed-citation></ref><ref id="pone.0332471.ref016"><label>16</label><mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: A language and environment for statistical computing</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>. <year>2021</year>.</mixed-citation></ref><ref id="pone.0332471.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nguyen</surname><given-names>MTB</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>CSY</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Gise</surname><given-names>R</given-names></name>. <article-title>Three-year Outcomes of Botulinum Toxin Versus Strabismus Surgery for the Treatment of Acute Acquired Comitant Esotropia in Children</article-title>. <source>Am J Ophthalmol</source>. <year>2025</year>;<volume>272</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2024.12.025</pub-id><pub-id pub-id-type="pmid">39755349</pub-id></mixed-citation></ref><ref id="pone.0332471.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cheung</surname><given-names>CSY</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Zurakowski</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kodsi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ekdawi</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>HC</given-names></name>, <etal>et al</etal>. <article-title>A Comparison of Chemodnervation to Incisional Surgery for Acute, Acquired, Comitant Esotropia: An International Study</article-title>. <source>American Journal of Ophthalmology</source>. <year>2024</year>;<volume>263</volume>:<fpage>160</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2024.02.036</pub-id><pub-id pub-id-type="pmid">38447598</pub-id></mixed-citation></ref><ref id="pone.0332471.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of augmented-dosed surgery versus botulinum toxin A injection for acute acquired concomitant esotropia: a 2-year follow-up</article-title>. <source>Br J Ophthalmol</source>. <year>2024</year>;<volume>108</volume>(<issue>7</issue>):<fpage>1044</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bjo-2023-323646</pub-id><pub-id pub-id-type="pmid">37620123</pub-id></mixed-citation></ref><ref id="pone.0332471.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gama</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Santos</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Nom</surname><given-names>TY</given-names></name>, <name name-style="western"><surname>da Costa</surname><given-names>DC</given-names></name>. <article-title>Differences of a Single Injection of Botulinum Toxin A between Infantile and Nonaccommodative Esotropia</article-title>. <source>J Binocul Vis Ocul Motil</source>. <year>2020</year>;<volume>70</volume>(<issue>3</issue>):<fpage>98</fpage>&#8211;<lpage>102</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/2576117X.2020.1777063</pub-id><pub-id pub-id-type="pmid">32511074</pub-id></mixed-citation></ref><ref id="pone.0332471.ref021"><label>21</label><mixed-citation publication-type="book"><name name-style="western"><surname>Hered</surname><given-names>R</given-names></name>. <article-title>Surgery for extraocular muscles</article-title>. <source>2018-2019 Basic and Clinical Science Course, Section 06: Pediatric Ophthalmology and Strabismus</source>. <publisher-loc>PA</publisher-loc>: <publisher-name>American Academy Ophthalmology</publisher-name>. <year>2018</year>. <fpage>241</fpage>&#8211;<lpage>2</lpage>.</mixed-citation></ref><ref id="pone.0332471.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Song</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>. <article-title>Efficacy of botulinum toxin injection versus bilateral medial rectus recession for comitant esotropia: a meta-analysis</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source>. <year>2023</year>;<volume>261</volume>(<issue>5</issue>):<fpage>1247</fpage>&#8211;<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00417-022-05882-5</pub-id><pub-id pub-id-type="pmid">36322214</pub-id></mixed-citation></ref><ref id="pone.0332471.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Niyaz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yeter</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Beldagli</surname><given-names>C</given-names></name>. <article-title>Success rates of botulinum toxin in different types of strabismus and dose effect</article-title>. <source>Can J Ophthalmol</source>. <year>2023</year>;<volume>58</volume>(<issue>3</issue>):<fpage>239</fpage>&#8211;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jcjo.2021.12.002</pub-id><pub-id pub-id-type="pmid">35038409</pub-id></mixed-citation></ref><ref id="pone.0332471.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rowe</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Noonan</surname><given-names>C</given-names></name>. <article-title>Complications of botulinum toxin a and their adverse effects</article-title>. <source>Strabismus</source>. <year>2009</year>;<volume>17</volume>(<issue>4</issue>):<fpage>139</fpage>&#8211;<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/09273970903303860</pub-id><pub-id pub-id-type="pmid">20001507</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pone.0332471.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332471.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pawar</surname><given-names initials="N">Neelam</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Neelam Pawar</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Neelam Pawar</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0332471" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">1 Aug 2025</named-content>
</p><p>PONE-D-25-34080Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropiaPLOS ONE</p><p>Dear Dr. Rattanalert,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Sep 15 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Neelam Pawar</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]</p><p>Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the &#8220;minimal data set&#8221; for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition" ext-link-type="uri">https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition</ext-link>).</p><p>For example, authors should submit the following data:</p><p>- The values behind the means, standard deviations and other measures reported;</p><p>- The values used to build graphs;</p><p>- The points extracted from images for analysis.</p><p>Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.</p><p>If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/recommended-repositories" ext-link-type="uri">https://journals.plos.org/plosone/s/recommended-repositories</ext-link>.</p><p>If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.</p><p>3. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.&#160;</p><p>4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#8217;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>Additional Editor Comments:</p><p>Emphasize on recurrence , post op diplopia and relapse cases.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;Dear Authors, thank you for your article.</p><p>Comments: Why did you considered 10 PD as a success result ? Wouldn't be more accurate to cover the fusional range considering the aspect that one of the stability factors after treatment is binocularity recovery ? At 10 PD ET diplopia can be still present (half of you cohort had pre-toxin diplopia).</p><p>I think your data would be more accurate keeping in your statistic only binocular injection.</p><p>In my opinion subsequent interventions are not relevant considering the study purpose.</p><p>It is possible that, stability after treatment to be influenced by other factors as lifestyle. I our days we confront with Acute Esotropia related to screen overuse, especially smartphones, re-occurrence of ET in not unusual after BT or surgery so, some other factors can be involved in the rate success at two years after injection.</p><p>Reviewer #2:&#160;I read this article titled as "Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia" with a great interest</p><p>1. Congratulations to authors for well written manuscript</p><p>2. Line 133-35 It would have been better to mention the recurrence rate ? 7 patients had recurrence</p><p>3. Current study brings out the fact that there is 51% success rate with BTXA treatment, with a trend of a decline in success over time. Interestingly only one-fourth of the patients sustained optimal outcomes beyond 2 years.</p><p>4.This study does not come up with new knowledge apart from most effective for small-to-moderate angle deviations which is very much known looking at the current literature.</p><p>5.Overall, the analysis of factors using univariate model underscores the potential the benefits of BTXA as an alternative treatment for acquired esotropia, and of course this possibly due to the retrospective nature of the study and overall small sample size representing each group of esotropia and less duration of follow up.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold> Daniela Eleonora Cioplean</p><p>Reviewer #2:&#160;<bold>Yes:&#160;</bold> Vivek Warkad</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0332471.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332471.r002</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" id="rel-obj002" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938886"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">14 Aug 2025</named-content>
</p><p>all comment was response. response to reviewers file was attached.</p><p>New N = 49</p><supplementary-material id="pone.0332471.s002" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers_NR 2025-08-14.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332471.s002.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0332471.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332471.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pawar</surname><given-names initials="N">Neelam</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Neelam Pawar</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Neelam Pawar</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938886"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">1 Sep 2025</named-content>
</p><p>Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia</p><p>PONE-D-25-34080R1</p><p>Dear Dr.&#160;Narisa Rattanalert</p><p>We&#8217;re pleased to inform you that yo,ur manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#8217;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#8217;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#174;</ext-link> &#160;and clicking the &#8216;Update My Information' link at the top of the page. For questions related to billing, please contact <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.my.site.com/s/" ext-link-type="uri">billing support</ext-link> .</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#8217;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Neelam Pawar</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewer #1:</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #1:&#160;All comments have been addressed</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;(No Response)</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold> Daniela Eleonora Cioplean</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0332471.r004" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332471.r004</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pawar</surname><given-names initials="N">Neelam</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Neelam Pawar</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Neelam Pawar</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0332471" id="rel-obj004" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-25-34080R1</p><p>PLOS ONE</p><p>Dear Dr. Rattanalert,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#160;instructions from the production team, including instructions on how to review your proof when it&#160;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://explore.plos.org/phishing" ext-link-type="uri">https://explore.plos.org/phishing</ext-link>.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Neelam Pawar</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article></pmc-articleset>